Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. ##STR00001##

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. ##STR00001##

Provided herein are the K-Ras inhibitors of the formulae: ##STR00001##
Also provided are compositions comprising thereof for treating cancer.

Provided herein are the K-Ras inhibitors of the formulae: ##STR00001##
Also provided are compositions comprising thereof for treating cancer.

The present application relates to fluorinated benzylsulfonamide hydroxamic acid compounds of Formula I and/or pharmaceutically acceptable salt, solvate and/or prodrug thereof: (I) for use as a inhibitor of HDAC6. The application also relates to methods of treating a disease, disorder or condition using the compounds and compositions of the application.

##STR00001##

The present application relates to fluorinated benzylsulfonamide hydroxamic acid compounds of Formula I and/or pharmaceutically acceptable salt, solvate and/or prodrug thereof: (I) for use as a inhibitor of HDAC6. The application also relates to methods of treating a disease, disorder or condition using the compounds and compositions of the application.

##STR00001##

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers. ##STR00001##

A composition which is useful for production of a light emitting device excellent in light emission efficiency is provided. In particular, provided is a composition containing a compound represented by formula (1) and a phosphorescent compound, wherein R.sup.1 and R.sup.2 each independently represent a substituent, n.sup.1 represents an integer of 1 to 14, and Ar.sup.1 represents an arylene group or a divalent heterocyclic group, and at least one of one or more groups Ar.sup.1 is a group represented by the formula (1-A), wherein the variable groups R.sup.1A to R.sup.8A, R.sup.91A, and R.sup.92A are as defined in the specification. ##STR00001##

A composition which is useful for production of a light emitting device excellent in light emission efficiency is provided. In particular, provided is a composition containing a compound represented by formula (1) and a phosphorescent compound, wherein R.sup.1 and R.sup.2 each independently represent a substituent, n.sup.1 represents an integer of 1 to 14, and Ar.sup.1 represents an arylene group or a divalent heterocyclic group, and at least one of one or more groups Ar.sup.1 is a group represented by the formula (1-A), wherein the variable groups R.sup.1A to R.sup.8A, R.sup.91A, and R.sup.92A are as defined in the specification. ##STR00001##

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.